CC:an immunotherapy for cancer-optimistically, might be more than one immunotherapy.. | NAVB Message Board Posts


Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  38212 of 38602  at  9/22/2022 10:52:35 PM  by

moneyonomics

The following message was updated on 9/22/2022 10:53:10 PM.

CC:an immunotherapy for cancer-optimistically, might be more than one immunotherapy..

 
Positive Funds Use Results on a tight budget
 
Unknown Attendee (Attendees)

Yes. This is a follow-up. Dr. Rosol, can you just provide any more color or depth on the 2 oncology-related preclinical trials ongoing that you're currently planning 2024 or earlier INDs? One is the M1, M2 and -- can you provide any more color on those?

Answer
Michael Rosol (Executives)

Sure. What we're doing is we're doing -- right now, we're doing preclinical studies to select our lead candidate to move first towards IND for first-in-human studies. And so you've heard me mention the various new payloads, new constructs. We have the Dox-Manocept construct that has some promising preliminary results.

There are reasons to believe that some of our other newer therapeutic payload constructs will have -- would have and will have superior efficacy. And so we've been advancing those as well preclinically. And we're getting very close to a phase where we can say, "This is our lead and these are our other candidates that we will also continue to advance behind those."

So things are moving. We'll be looking to do some investigator-initiated studies to help us advance towards IND and possibly investigator-initiated IND. So we'll work closely with research collaborators at well-known institutions who can help us get these into humans more rapidly and do those first human studies rapidly as well.

So when that slide was crafted, it was really about taking an anti -- an immunotherapy for cancer to IND as well as an anti-inflammatory. And at the end of the day, optimistically, it might be more than one immunotherapy, give or take a year between the 2,
 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...